Histone deacetylase inhibitors: a patent review (2009 – 2011)

Recent Developments of Small Molecule EGFR Inhibitors Based on the Quinazoline Core Scaffolds

(2012) Yu-Jing Liu et al.   Anti-Cancer Agents in Medicinal Chemistry

Genomics and Cancer Drug Resistance

(2012) Antonio S. Rodrigues et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer

(2012) Asuka Nakata et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Targeting Epigenetic Readers in Cancer

(2012) Mark A. Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutagenesis of pairwise combinations of histone amino-terminal tails reveals functional redundancy in budding yeast

(2012) J.-A. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming

(2012) Androniki Kretsovali et al.   Stem Cells International

Sirtuins and Disease: The Road Ahead

(2012) Vincenzo Carafa et al.   Frontiers in Pharmacology

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

(2011) Omar Khan et al.   IMMUNOLOGY AND CELL BIOLOGY

Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008

(2011) A. Nebbioso et al.   MOLECULAR CANCER THERAPEUTICS

Unknown

(2011) Charles Dinarello et al.   MOLECULAR MEDICINE

H3K9 histone acetylation predicts pluripotency and reprogramming capacity of ES cells

(2011) Hadas Hezroni et al.   Nucleus

Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells

(2010) Hussein Fakhry et al.   HUMAN PATHOLOGY

HDAC Inhibitor-Mediated Radiosensitization in Human Carcinoma Cells: A General Phenomenon?

(2010) In Ah KIM et al.   JOURNAL OF RADIATION RESEARCH

Rational Combinations Using HDAC Inhibitors

(2009) M. Bots et al.   CLINICAL CANCER RESEARCH

Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes

(2009) Angela Nebbioso et al.   EMBO REPORTS

Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's Disease

(2009) Mark Kilgore et al.   NEUROPSYCHOPHARMACOLOGY

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

(2008) Nagma Khan et al.   BIOCHEMICAL JOURNAL

2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors

(2008) Philip Jones et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Non-Invasive Tests in Animal Models and Humans: A New Paradigm for Assessing Efficacy of Biologics Including Prebiotics and Probiotics

(2008) R. Butler   CURRENT PHARMACEUTICAL DESIGN

Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents

(2008) Oscar Moradei et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and Carcinoma

(2008) Hassan Ashktorab et al.   DIGESTIVE DISEASES AND SCIENCES

Structural Origin of Selectivity in Class II-Selective Histone Deacetylase Inhibitors

(2008) Guillermina Estiu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Histone acetylation and chromatin signature in stem cell identity and cancer

(2007) Vivek Shukla et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS